Elan sees losses double in Q3

Pharmaceutical company Elan has seen its losses almost double to $117m (€93m) from $67m (€53m) in the three months to end of September, when compared with the same period last year.

However, losses for the nine months to the end of September were down, from $325.3m (€259m) in 2005 to $240.8m (€192m) this year.